xinkeqing higenamine hydrochloride injection 2 ml2

Description

Indication & Scope

XinKeQing® (Higenamine Hydrochloride Injection) is a Class 1 innovative chemical drug developed in China for use as a pharmacologic cardiac stress agent in myocardial perfusion imaging (MPI). It is indicated for radionuclide myocardial perfusion imaging to assess myocardial ischemia in patients requiring pharmacologic stress testing.

Mechanism: Higenamine hydrochloride is a β-adrenergic receptor agonist that produces positive inotropic and chronotropic effects, increasing myocardial contractility, heart rate, and coronary blood flow to induce pharmacologic cardiac stress.
Drug class: β-Adrenergic receptor agonist.
Clinical use: Pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) to evaluate myocardial ischemia.

Specification

Generic Name	Higenamine Hydrochloride
Brand Name	XinKeQing®
Ingredient	Higenamine Hydrochloride
Dosage Form	Injection
Package	2 mL:2.5 mg × 1 vial
Conditions Treated	Myocardial ischemia assessment by myocardial perfusion imaging (MPI)
Taboos	Hypersensitivity to higenamine hydrochloride or any component of the product.
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Refer to the approved package labeling.
Manufacturer	Zhuhai Rundu Pharmaceutical Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	H20260017
Date of Revision	2026
Shelf Life	Refer to the approved package labeling

How to use ?

Recommended Dose: Dilute one vial with 0.9% Sodium Chloride Injection to a total volume of 50 mL (50 μg/mL). Administer intravenously using an incremental infusion protocol of 0.5, 1.0, 2.0, and 4.0 μg/kg/min, with each dose infused for 3 minutes (total infusion time: 12 minutes).

Time: Administer immediately before radionuclide myocardial perfusion imaging (MPI). Inject the radiopharmaceutical tracer immediately after the cardiac stress test endpoint is reached.

Instructions for use: For intravenous use only. Prepare immediately before administration. Stop the infusion immediately once the cardiac stress test termination criteria are met, and proceed with radionuclide myocardial perfusion imaging according to the approved protocol.

Interaction: Refer to the approved package labeling.

Side effects: Adverse reactions are generally mild and usually resolve rapidly after discontinuation. Refer to the approved prescribing information for complete safety information.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is XinKeQing® (Higenamine Hydrochloride Injection)?

XinKeQing® is a pharmacologic cardiac stress agent used for radionuclide myocardial perfusion imaging (MPI).

How does XinKeQing® work?

It stimulates β-adrenergic receptors to increase heart rate and myocardial contractility, creating pharmacologic cardiac stress for MPI.

How is XinKeQing® administered?

It is administered by intravenous infusion using an incremental dosing protocol under the supervision of qualified healthcare professionals.

Who is XinKeQing® intended for?

It is intended for patients requiring pharmacologic cardiac stress during myocardial perfusion imaging, particularly those unable to undergo adequate exercise stress testing.